These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 18635756)

  • 21. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment.
    Hoshide S; Takahashi Y; Ishikawa T; Kubo J; Tsuchimoto M; Komoriya K; Ohno I; Hosoya T
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1117-8. PubMed ID: 15571212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
    Goldfarb DS; MacDonald PA; Hunt B; Gunawardhana L
    J Rheumatol; 2011 Jul; 38(7):1385-9. PubMed ID: 21572152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of febuxostat in healthy Chinese volunteers.
    Liu XX; Liu RJ; Ding L; Lin YF; Huang NY; Xiao HF; Huang Y; Yang J; Wang SL
    Arzneimittelforschung; 2012 Oct; 62(10):463-9. PubMed ID: 22956350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Febuxostat for prevention of gout attacks.
    Pohar S; Murphy G
    Issues Emerg Health Technol; 2006 Aug; (87):1-4. PubMed ID: 16958189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Febuxostat versus allopurinol for gout.
    Gelber AC
    N Engl J Med; 2006 Apr; 354(14):1532-3; author reply 1532-3. PubMed ID: 16602151
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in kidney transplant recipients.
    Tojimbara T; Nakajima I; Yashima J; Fuchinoue S; Teraoka S
    Transplant Proc; 2014; 46(2):511-3. PubMed ID: 24656001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S19-26. PubMed ID: 21654266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects.
    Yoon S; Shin D; Lee H; Jang IJ; Yu KS
    Drug Des Devel Ther; 2015; 9():5033-49. PubMed ID: 26357467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Febuxostat (Uloric) for chronic treatment of gout.
    Med Lett Drugs Ther; 2009 May; 51(1312):37-8. PubMed ID: 19448587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout.
    Yu KH
    Recent Pat Inflamm Allergy Drug Discov; 2007 Feb; 1(1):69-75. PubMed ID: 19075968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.
    Takano Y; Hase-Aoki K; Horiuchi H; Zhao L; Kasahara Y; Kondo S; Becker MA
    Life Sci; 2005 Mar; 76(16):1835-47. PubMed ID: 15698861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout.
    Yue CS; Huang W; Alton M; Maroli AN; Waltrip RW; Wright D; Marco MD
    J Clin Pharmacol; 2008 Jun; 48(6):708-18. PubMed ID: 18420531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.
    Mayer MD; Khosravan R; Vernillet L; Wu JT; Joseph-Ridge N; Mulford DJ
    Am J Ther; 2005; 12(1):22-34. PubMed ID: 15662289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Febuxostat].
    Wittköpper K; Emons J; El-Armouche A
    Dtsch Med Wochenschr; 2011 Jun; 136(23):1270-4. PubMed ID: 21607898
    [No Abstract]   [Full Text] [Related]  

  • 39. Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.
    Prescrire Int; 2009 Apr; 18(100):63-5. PubMed ID: 19585722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.
    Sánchez-Lozada LG; Tapia E; Soto V; Avila-Casado C; Franco M; Zhao L; Johnson RJ
    Nephrol Dial Transplant; 2008 Apr; 23(4):1179-85. PubMed ID: 18048425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.